Market news

argenx (ENXTBR:ARGX) has completed its acquisition of Forte Biosciences, adding antibody candidate FB102 to its immunology pipeline. The transaction supports argenx's Vision 2030 plan to broaden its presence in autoimmune disease treatment. FB102 is expected to be integrated into argenx's existing research and development programs focused on immunology. For readers who want more ideas in advanced immunology and related technologies, the next step is to explore 134 healthcare AI...

Acquisition adds first-in-class anti-CD122 Antibody, FB102, to argenx’s immunology pipeline

argenx (ENXTBR:ARGX) is set to consider and discuss the acquisition of Forte Biosciences, Inc. The potential deal would expand argenx's reach in biopharmaceutical research and development. Management attention on the proposed acquisition could influence argenx's capital allocation priorities. Investors are watching for details on valuation terms and integration plans once disclosed. This kind of transaction is one part of a broader opportunity set in biopharma and beyond, so it can be...

Argenx (ARGX) announced the acquisition of Forte Biosciences (FBRX) at $77 per share on July 27. FBRX saw significant price movement beginning June 29, weeks before the public announcement. Both FBRX and ARGX exhibited notable trading activity ahead of the deal, suggesting possible insider knowledge influencing price action. This case...

The biopharma sector is in the middle of a transformation in which macroeconomic pressures and policy developments actively dictate corporate dealmaking. As leading pharmaceutical companies prepare for a $300 billion patent cliff in the second half of the decade, capital allocation has switched sharply toward restocking commercial pipelines with low-risk, high-conviction clinical assets. At the […]

argenx SE has entered into a definitive agreement to acquire Forte Biosciences through a cash tender offer. The boards of both companies have approved the transaction, which is expected to close soon, subject to customary conditions. The deal will result in a change of control for Forte Biosciences, with all remaining shares acquired after completion of the tender. For existing and potential shareholders, Forte Biosciences, NasdaqCM:FBRX, now sits squarely in deal territory. The stock most...

The transaction is expected to close in the third quarter of 2026.

argenx (ENXTBR:ARGX) is back in focus after agreeing to acquire Forte Biosciences in an all cash deal valued at about US$2.2b, centered on Forte’s anti CD122 antibody program FB102. See our latest analysis for argenx. argenx shares have had a strong run, with a 1 year total shareholder return of 54.32% and a 5 year total shareholder return of 202.61%. The 90 day share price return of 18.66% and the recent Forte deal suggest momentum has been building into recent earnings and pipeline...

Forte Biosciences stock soars on a $2.2 billion takeover proposal from Argenx. But is there any further upside left in FBRX shares? Let’s find out!

Dow Jones up 400 points on Monday. Baker Hughes Co (BKR) shares rise after positive earnings and technology order. Other big gainers include NIPG, FBRX, TRAX, GENI, BMNR, OMER, ASAN, EIKN, IONQ, and SPT.

These are the stocks posting the largest moves premarket.

Forte Biosciences (NASDAQ:FBRX) shares climbed 39. 2% in pre-market trading after argenx (NASDAQ:ARGX) announced a definitive agreement to acquire the clinical-stage biotechnology company in an all-cash transaction valued at approximately $2.

Argenx NV ADR (NASDAQ:ARGX) has agreed to acquire Forte Biosciences Inc (NASDAQ:FBRX) in a transaction valued at approximately $2. 2 billion, expanding its portfolio of autoimmune disease treatments as it looks to build new growth opportunities beyond its flagship medicine, Vyvgart.

Forte Biosciences shares rose 38.9% to $76.10 in pre-market trading after argenx SE announced plans to acquire the company for $77 per share.

The deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among multiple developers.

(Updates to add recent stock move for Forte Biosciences in the last paragraph.) Argenx (ARGX) and

Forte Biosciences (NASDAQ:FBRX) shares surged about 40% to around $76 on Monday after argenx (NASDAQ:ARGX) announced an agreement to acquire the biotechnology company in a deal valued at approximately $2.2 billion. Under the terms of the agreement, argenx will acquire all outstanding Forte...

Argenx (ARGX) and Forte Biosciences (FBRX) said Monday that Argenx has agreed to buy Forte for $77 p

Forte Biosciences (FBRX) shares surged early Monday after the company agreed to be acquired by Belgi

Forte Biosciences stock soars after early-stage data show FB102 significantly improves facial depigmentation in vitiligo with a favorable safety profile.